A 25-gene classifier predicts overall survival in resectable pancreatic cancer

David Birnbaum (1, 2) , Pascal Finetti (2) , Alexia Lopresti (2) , Marine Gilabert (2) , Flora Poizat (3) , Jean-Luc Raoul (3) , Jean-Robert Delpero (4) , Vincent Moutardier (1) , Daniel Birnbaum (2) , Emilie Mamessier (2) , François Bertucci (2)

1 AMU MED - Aix-Marseille Université - Faculté de médecine
2 CRCM - Centre de Recherche en Cancérologie de Marseille
3 IPC - Institut Paoli-Calmettes
4 Department of Surgical Oncology

Background: Pancreatic carcinoma is one of the most lethal human cancers. In patients with resectable tumors, surgery followed by adjuvant chemotherapy is the only curative treatment. However, the 5-year survival is 20%. Because of a strong metastatic propensity, neoadjuvant chemotherapy is being tested in randomized clinical trials. In this context, improving the selection of patients for immediate surgery or neoadjuvant chemotherapy is crucial, and high-throughput molecular analyses may help; the present study aims to address this.

Domaines: Sciences du Vivant [q-bio]; Cancer; Biochimie, Biologie Moléculaire; Génomique, Transcriptomique et Protéomique [q-bio.GN]

David Birnbaum, Pascal Finetti, Alexia Lopresti, Marine Gilabert, Flora Poizat, et al.. A 25-gene classifier predicts overall survival in resectable pancreatic cancer. BMC Medicine, 2017, 15 (1), ⟨10.1186/s12916-017-0936-z⟩. ⟨hal-01787872⟩